
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. anticipates a rebound in enterprise sales from integrated delivery networks (IDN) this year, which aligns with the expected improvement in the macroeconomic environment. The company is making significant advancements in its claims pipeline, which bodes well for the potential of its Indego Personal product as a substantial revenue driver in 2025 and beyond. Additionally, strategic partnerships aimed at enhancing the growth of Indego Personal further support a positive financial outlook for the company.
Bears say
Ekso Bionics Holdings Inc. reported total revenue of $3.4 million in the first quarter of 2025, reflecting a 10% year-over-year decline from $3.8 million in the same period in 2024 and falling short of consensus expectations of $4.6 million. The company has revised its revenue outlook for the EksoHealth channel downward for 2025 and beyond, anticipating adverse effects from ongoing economic uncertainty. Additionally, the presence of softer enterprise revenue attributed to customer budget cuts raises further concerns about the company's growth potential in key markets.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares